Premium
Management of Antiplatelet Therapy for Minimization of Bleeding Risk Before Cardiac Surgery
Author(s) -
Weant Kyle A.,
Flynn Jeremy F.,
Akers Wendell S.
Publication year - 2006
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.26.11.1616
Subject(s) - medicine , myocardial infarction , antiplatelet drug , angina , pharmacodynamics , stroke (engine) , coronary artery bypass surgery , drug , artery , unstable angina , clinical trial , cardiology , clopidogrel , surgery , pharmacokinetics , pharmacology , mechanical engineering , engineering
Antiplatelet therapy is commonly administered for primary and secondary prevention of stroke, recurrent angina, myocardial infarction, and death in patients with cardiovascular disorders. It also is associated with an increased risk of bleeding. We describe the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. In addition, we provide basic information about the mechanisms of action by which the most common antiplatelet agents inhibit platelet function. This information is integrated with results from pharmacologic studies and clinical trials. Determining the net effect in patients undergoing coronary artery bypass graft surgery requires knowledge about the pharmacokinetics, pharmacodynamics, and clinical efficacy of each drug, and an estimation of the absolute thrombotic versus hemorrhagic risk for each patient.